Table 2

Characteristics of cancers in juvenile-onset arthritis

Cancer typeSexRaceArthritis TypeAge at cancerDMARDBiologicVital status†Country‡Arthritis§ durationCancer date
Hodgkin's lymphomaMWhiteEnthesitis-related18NoNoAliveCA22005
B-cell lymphocytic leukaemiaFFirst NationPolyarticular rheumatoid factor negative 9YesNoDeceasedUSA42002
Hepatosplenic T-cell NHLFWhiteSystemic16YesYesDeceasedCA82009
Polymorphic post-transplantation lymphoproliferative diseaseMWhitePolyarticular rheumatoid factor positive16YesYesDeceasedUSA32010
Papillary follicular adenocarcinoma thyroidFWhiteOligoarticular persistent13NoNoAliveUSA82011
Renal cell adenocarcinomaFWhitePolyarticular rheumatoid factor negative24YesYesAliveCA192008
GliomaMWhiteOligoarticular persistent10NoNoAliveCA52008
Primitive neuroectodermal (Ewing) cancerFWhiteOligoarticular extended17YesYesDeceasedCA62009
Endometrial adenocarcinomaFWhiteEnthesitis-related30YesYesAliveCA142011
  • *Prior DMARD=use of disease-modifying antirheumatic agent prior to cancer onset.

  • †Vital status as of time of cancer registry linkage.

  • ‡CA=Canada.

  • §Time between arthritis diagnosis and cancer diagnosis.

  • Prior to the B-cell lymphocytic leukaemia, the patient received MTX for 1 year prior to the hepatosplenic T-cell NHL, the patient was on MTX for 3.6 years, etanercept for 0.1 year, then infliximab for 1.7 years, then anakinra for 1.9 years. Prior to the post-transplant lymphoproliferative disorder, the patient had been on MTX for 1 month, etanercept for 6 months, cyclophosphamide for 1 year 3 months and infliximab for 4 months prior to the transplant, and mycophenolate, tacrolimus, rituximab and cyclophosphamide thereafter. Prior to the renal cell cancer, the patient was on MTX for 6.2 years, then leflunomide for 0.2 years, then etanercept for 4.8 years. Prior to the diagnosis of primitive neuroectodermal (Ewing) cancer, the patient was exposed to MTX for at least 20 months and leflunomide for 3 months, and was prescribed Enbrel but was not compliant.

  • DMARD, disease-modifying antirheumatic drug; F, female; M, male; MTX, methotrexate; NHL, non-Hodgkin's lymphoma.